METTL14 Antibodies

N6-adenosine-methyltransferase non-catalytic subunit (METTL14)

The METTL3-METTL14 heterodimer forms a N6- methyltransferase complex that methylates adenosine residues at the N(6) position of some mRNAs and modulates the circadian clock, differentiation of embryonic stem cells and cortical neurogenesis (PubMed:24316715, PubMed:24407421, PubMed:25719671, PubMed:29348140, PubMed:27373337, PubMed:27281194). In the heterodimer formed with METTL3, METTL14 constitutes the RNA- binding scaffold that recognizes the substrate as opposed to the catalytic core (PubMed:27627798, PubMed:27373337, PubMed:27281194, PubMed:29348140).

N6-methyladenosine (m6A), which occurs at the 5'-[AG]GAC-3' consensus websites of some mRNAs, plays a role in mRNA stability and processing (PubMed:24316715, PubMed:24407421, PubMed:25719671). M6A acts as a key regulator of mRNA stability by promoting mRNA destabilization and degradation (By similarity).

Gene Information

Human
Gene Name:	METTL14
Uniprot:	Q9HCE5
Entrez:	57721

Family

Belongs to:
MT-A70-like family

Alternative Names

EC 2.1.1; EC 2.1.1.-; KIAA1627; KIAA1627methyltransferase-like protein 14; methyltransferase like 14; METTL14

Molecular Weight

Mass (kDA):
52.15 kDA

Genomic Context

Human
Location:	4q26
Sequence:	4; NC_000004.12 (118685375..118715430)

Subcellular Localizations

Nucleus.

Diseases

• Neoplasms

Interacting Proteins

• METTL3

Pathways

• Cell Proliferation
• Regulation Of Cell Proliferation

PTMs

• Phosphoprotein

Research Areas

• Lipid and Metabolism

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/METTL14

Best Uses Of The METTL14 Marker

You may be curious about the best methods to utilize the METTL14 marker to conduct biochemical research in your lab. This article will answer this question. Boster Bio offers products that will help you in the process. There are RT-qPCR, ELISA, and METTL14 Marker. Continue reading to learn more.

RT-qPCR

RT-qPCR is the gold standard method used to study gene expression. Although PCR arrays can be used to investigate gene expression, there are a variety of instruments that do not have technical replicates. This can result in poor results. Furthermore, the amplification of each target in one well is not able to allow for the detection of errors that occur. This technique is perfect to investigate the effects of drugs on the expression of genes.

However, RT-qPCR isn't 100% accurate. It requires the use of 3 genes that are controlled. These controls are not able to guarantee homogeneity of the RNA. A single instrument can't handle more than one million samples every day. One instrument is not able to perform all tests required. Additionally, some instruments may be in need of repair, which restricts their usage in diagnostic tests.

To assess the reliability of the METTL14 marker we conducted a qPCR analysis using the RNXtract kit. We analyzed the reliability of the quantification of RNA by using two methods: RNA extracted from clinical samples and RNA extracted from non-invasive cancer tissue. In our study, we utilized samples that had low cancer cell count but were still macrodissected to a degree of 80 percent. In addition, we also included DCIS in varying degrees adjacent to the tumor.

Testing RTQPCR assays for lower template RNA and test detection capabilities was vital. To assess the quality of RT-qPCR it was recommended that the Clinical and Laboratory Standards Institute released the EP17-A guidelines. The test was carried out on six different tumor biopsies aswell as three RNA eluates which corresponded to different subtypes. The test results were compared to acceptable levels of B2M and CALM2 REF genes to determine the quality of each sample.

RT-qPCR is an effective method to detect SARS/CoV-2 genes. It is also the first technique to detect the SARS-2 genome in an infected person. Further improvements in RT-qPCR testing are likely to be available within the next few weeks. If you've not had an chance to test for the SARS-CoV-2 infection, think about contacting your local health department to ensure that you do not contract the disease.

Utilizing the METTL14 gene as a template for RT-qPCR is simple and efficient. The METTL14 marker can be utilized in a variety of experiments. METTL14 is extremely sensitive and is used in a variety of research projects. If you want to determine the presence of this marker, then consider RT-qPCR as a viable alternative.

A METTL14 mutation in a patient may cause premature neuron differentiation. Mettl14 mutations can result in an increase in NSC proliferative capacity. Overexpression leads to an increase in the number of neurospheres. The main regulator of NSC self renewal is also METTL14. Therefore, mutations in METTL14 result in premature neuron differentiation and can lead to neurodevelopmental problems.

The COVID-19-RT-qPCR Detection Kit detects a virus in blood samples. It is a sensitive diagnostic tool that can detect moderate to low-level infections. It is approved for clinical labs. However it is essential to note that it is designed for use by experienced and certified personnel. It should be used according to the Food and Drug Administration's emergency use authorization.

ELISA

METTL14 is a posttranscriptional modification to the mRNA that regulates transcription splicing and protein translation. It is involved in a variety of human illnesses, including brain disease and abnormal cell differentiation. However, its role in podocyte damage is largely unknown, though it has been associated with kidney disease and inflammatory colon disease. At present, however we know little about the mechanisms of regulation that regulate its expression.

The effects of ADR treatment on podocytes were studied with a METTL14 knockdown. This gene was knocked down to inhibit the proapoptotic mediators of IL-6 as well as TNF-a. This suggests that METTL14 reduces AGE induced podocyte inflammation. Future studies will look into whether METTL14 knockdown diminishes the effects of ADR.

Another method of ELISA using the METTL14 protein is to use enzymes to label primary antibodies. The enzymes used in this method include horseradish peroxidase, phosphatase, alkaline phosphatase, and other enzymes. In some cases, other enzymes, like b-galactosidasecan be employed as labels. The physiologic buffer is typically Tween-20-based. Blocking buffer is a mix of detergent and Tween-20.

METTL3 and MTTL14 are necessary to perform the proper WMM complex function. WTAP is reduced by obesity caused by diet. Likewise, WTAP promotes adipocyte differentiation. In vitro and in vivo experiments show that knockdown of METTL3 or MTTL14 could hinder cell cycle transition. Thus, adipocyte differentiation depends on WTAP.

METTL14 promotes m6A modification of Sirt1 mRNA. The m6A reader proteins control the degrading of m6A by m6A. YTH domain family proteins, heterogeneous nuclear nucleoprotein, and eIF all recognize the modifications to m6A. YTHDF2 mediates mRNA decay and has a conserved G(m6A)C central motif.

METTL14 knockdown in db/db mice results in renal injury. The rAAV-METTL14 variant, on the other hand, reduces renal injury by increasing the serum levels of TNF-a/IL-6. The rAAV-Klotho inhibitor reverses this effect. These findings suggest that METTL14 is a key regulator of increased m6ARNA modification.

The m6A methyltransferase proteins METTL3 and METTL14 play a vital role in regulating the expression of genes in tumor cells. Both Mettl3 and METTL14 regulate gene expression via readers. They regulate the expression of genes in downstream pathways. This was confirmed by generating CT26 cells that express Stat1 or Irf1 with a knockout of Ythdf1-3. After stimulation with IFN-g, the mRNA levels of both genes increased.

Mettl14 plays a part in regulation of m6A within macrophages. Mettl14 knockdown reduces macrophages' capability to adhere to the cells of the endothelial. This inhibition also inhibits their adhesion and migration to the inflammation-inducing environment.

The expression of WTAP is widely expressed, and its role in regulating adipocyte differentiation is not clear. Its function was initially believed to be related to its connection with METTL3 and METTL14. The gene complexes with the cell cycle regulators METTL3 and METTL14. The WTAP complex also plays a role in posttranscriptional metabolism of mRNA.

To test for an ELISA of the METTL14 gene, various lysates were processed for western blotting and SDS-PAGE. The specific antibody 26158-1-AP was used to detect the METTL14 marker. The ELISA for the METTL14 marker, METTL3, and METTL14 was conducted on these samples. After 60 hours of culture, the results were reported.

The m6A installation is made easier by the METTL14 methyltransferase methyltransferas. It is composed of the METTL3 core as well as other subunits. In addition to METTL3, METTL14 is responsible in reversing the m6A-mediated modification and activates m6A signaling. The complex METTL3-METTL14 also regulates Stat1 and ALKBH5 transcription.

The METTL14 test can be used to determine the presence of METTL14 in serum. ELISA is a non-invasive way to determine the presence of METTL14 protein in serum or plasma. METTL14 expression can be extremely variable in human cells. However the METTL14 ELISA can detect its concentration and reveal its presence within the blood.

To conduct a METTL14 ELISA you must prepare two sample matrices. The first substrate must contain an ELISA solution with a fluorescent color. The second substrate should be an insoluble ELISA solution. The ELISA will show the METTL14 methylation when the reaction is complete. The results of this ELISA will be apparent immediately. The optimal amount of fluorescent substrate must be used for the METTL14 ELISA.